41 results about "Dendritic cell vaccine" patented technology

The invention provides an anti-pancreatic cancer dendritic cell vaccine as well as a preparation method and application thereof, and belongs to the technical field of tumor vaccines. The anti-pancreatic cancer dendritic cell vaccine comprises dendritic cells loaded with at least one of the following antigens: induced pluripotent stem cell lysate and induced pluripotent stem cell exosome. The vaccine can obviously stimulate proliferation of T cells and can specifically induce proliferation of CD8 + T lymphocytes, so that the vaccine has obvious killing activity on three pancreatic cancer tumor cell lines. Meanwhile, the vaccine shows a good anti-pancreatic cancer effect in preventive inoculation in a human immune reconstruction mouse pancreatic cancer tumor model.

The invention relates to preparation of a pancreatic cancer dendritic cell vaccine and application of the pancreatic cancer dendritic cell vaccine in treatment of pancreatic cancer, relates to the technical field of biological medicines, and comprises a preparation method of Panc-1 and AsPC-1 lysates, a preparation method of a DC vaccine loaded with the Panc-1 and AsPC-1 lysates and function verification of DC cells. The DC vaccine prepared by the invention not only stimulates T cells to generate more IFN-gamma, but also induces to generate stronger tumor killing T cells, and provides a new thought for research and development of pancreatic cancer DC vaccines. In addition, Panc-1 and AsPC-1 lysates are adopted as antigens of the DC vaccine, so that the problem that autologous tumor antigens are difficult to obtain is solved. Furthermore, Panc-1 and AsPC-1 lysates are adopted as antigens of the DC vaccine, and the mixed lysates contain abundant and wide tumor antigens and can prevent immune escape of tumors.

Provided are an in vitro activated mixed cell cancer vaccine containing dendritic cells and B cells, and a use thereof. The mixed cell vaccine is obtained by simultaneously activating dendritic cells and B cells in vitro by means of antigen delivery particles; the antigen delivery particles are nanoparticles and / or micronparticles loaded with an antigen component; the antigen component is derived from one or more of the following: (1) a water-soluble component and / or a non-water-soluble component in cancer cells and / or cells in a tumor tissue; (2) a protein and a polypeptide component in the water-soluble component and / or non-water-soluble component; (3) an RNA component in the water-soluble component and / or non-water-soluble component; (4) a protein and / or polypeptide synthesized in vitro and containing an antigen polypeptide epitope; and (5) a nucleic acid synthesized in vitro and capable of expressing an antigen polypeptide epitope. In the present invention, the current technical prejudice against the effect of initial activation of T cells by B cells is overcome, and it is found that the mixed cell vaccine system of dendritic cells and B cells is significantly more effective than existing dendritic cell vaccines.

The present disclosure belongs to the field of biotechnology, and specifically relates to a preparation method for an adenovirus p53 (Ad-p53)-loaded dendritic cell (DC) vaccine. The present disclosure includes steps of peripheral blood collection and peripheral blood mononuclear cell (PBMC) separation, PBMC sorting, DC activation, Ad-P53-transfected DC and DC vaccine preparation. P53 can be expressed on a surface of DC as a tumor-associated antigen (TAA) through DC purification, specific multiplicity of infection (MOI) and infection modes, and the Ad-P53-transfected DC has obvious antigen presentation effect, which can be used as a vaccine to activate T cells to kill tumors.

The invention discloses a preparation method and application of a dendritic cell vaccine. The preparation method of the dendritic cell vaccine comprises the following steps: designing a new antigen mRNA sequence; preparing virus-like particles containing annular mRNA according to a new antigen mRNA sequence; dC is transfected through virus-like particles containing annular mRNA, and the DC vaccine of the tumor new antigen is obtained. The DC vaccine of the annular mRNA can be individually designed and prepared according to an amino acid sequence or a nucleotide sequence of a tumor neoantigen, accurate application of different individuals is realized, the stability of the annular mRNA in cells is higher, the annular mRNA can be directly expressed in the cells, and antigen information is more efficiently ingested and presented by the DC.

The present disclosure relates to a kit, which includes a tumor neoantigen nanoformulation and a dendritic cell vaccine. The kit disclosed in the present disclosure can significantly improve the uptake and presentation of antigens by antigen-presenting cells, activate and enhance the body's anti-tumor immune response, and effectively inhibit tumor progression. The combined therapy of tumor neoantigen nanoformulation and dendritic cell vaccine provides a new idea for personalized and precise treatment of cancer, which has clinical practical significance.

The present invention discloses an EBV complex antigen, a dendritic cell vaccine and its use in preparing a drug for treating EBV-related infections, which belongs to the technical field of biopharmaceuticals. The present invention stimulates the patient's own dendritic cells in vitro, loads them with lysates of various EBV-infected cells that have super-potent immunogenicity against EBV-related infections, and induces maturation in the presence of various cytokines and specific agonists to form a complete dendritic cell vaccine with the corresponding antigen, which is then returned to the human body to activate the immune system, generate cytotoxic T cells to kill EBV-infected cells, and exert immunological effects to improve the quality of patient vital activity. The production cycle of the dendritic cell vaccine is about one week, and it is short, low-cost, safe and has almost no side effects.

The invention discloses a dendritic cell multi-antigen loaded immunotherapy method, and a TLR7 agonist compound provided by the invention can strongly activate dendritic cells, significantly enhance the antigen presentation ability of the dendritic cells, and generate a synergistic effect with the dendritic cells loaded with antigens. The immunogenicity of the vaccine is improved, a wider immune cell network can be adjusted, and the anti-tumor immune response is comprehensively enhanced. Through the precisely designed compound structure, the scheme specifically enhances the immune response aiming at the HPV related antigen, and improves the targeting and effectiveness of treatment. The use of the compound is helpful for breaking the immune tolerance of an organism to tumor antigens and exciting stronger immune response. Compared with the pure use of the dendritic cell vaccine, the scheme improves the overall efficacy, possibly reduces the treatment times, and improves the compliance of the patient. Meanwhile, the scheme provides new possibility for individualized immunotherapy of cervical cancer, and precise therapy is realized.

The invention provides a dendritic cell vaccine for treating bone and soft tissue sarcoma as well as a preparation method and application of the dendritic cell vaccine. The dendritic cell vaccine comprises mature dendritic cells obtained by co-culturing sarcoma cell lysate and immature dendritic cells. The lysates of seven sarcoma cells are used as dendritic cell vaccine antigens, the problem that an existing DC vaccine is single in loaded antigen is solved, antigen presentation and T cell activation are enhanced, wide immune response is excited, immune escape is reduced, and the dendritic cell vaccine is not limited by the type of MHC of a patient, is high in universality and can benefit more patients.

The application belongs to the field of biological pharmacy, and particularly relates to application of a Caerin polypeptide combined with a dendritic cell vaccine in preparation of a drug for treating breast cancer. The application finds that F1 / F3 significantly inhibits proliferation of 4T-1 cells and induces cell death in vitro, significantly inhibits growth of a primary tumor, reduces lung metastasis, and prolongs overall survival in vivo, and inoculation of a DC vaccine loaded with a tumor-related antigen can reduce tumor growth and enhance T cell activation in draining and non-draining lymph nodes. Compared with a vaccine loaded with a whole antigen (DCV1), a DC vaccine (DCV2) combined with F1 / F3 induced 'programmed death antigen' exhibits stronger anti-tumor activity, although TNF-alpha and IL-12 secretion thereof is lower. Therefore, the application combines the F1 / F3 polypeptide with the DCV2 to prepare a drug for treating breast cancer, effectively improves the treatment effect on the tumor, and highlights the importance of a combined immunotherapy strategy.

The invention discloses a method for preparing a dendritic cell vaccine through in-vitro amplification and induction of hematopoietic stem cells, and belongs to the field of biomedicine.The amplification induction method specifically comprises the following steps that firstly, peripheral blood is collected, the collected peripheral blood is diluted, and then peripheral blood mononuclear cells are separated; according to the invention, the conditions that cells enter an inflammatory emergency state due to a large dose of IL-4 in a traditional scheme, metabolic routes such as cell glycolysis are highly activated, ROS release is caused by oxidative stress, and cell dysfunction is caused by abnormal metabolism are avoided, and a cell combination closest to real DC cell phenotype and function in a human body can be obtained; the antigen presentation of the DC vaccine is improved to the maximum extent, meanwhile, hematopoietic stem cells can be partially differentiated to a myeloid system, DC progenitor cells and DC precursor cells, effective amplification of dozens of times can be achieved in quantity, and the technical bottleneck that the clinical curative effect is limited due to insufficient cell quantity is solved.

The application discloses an engineered potent dendritic cell vaccine and a preparation method and application thereof, and utilizes a nano-scale antigen delivery mode to fuse tumor antigens with cationic liposomes, destroys the stability of a lysosome membrane by means of cationic liposome charge interaction, makes part of the antigens escape into a cytoplasm to be cross-presented through an MHC I pathway, gives the DCs the ability to activate a cellular immune response to resist tumors, on the other hand, gives the DCs T cell directivity through a synthetic immunology method, promotes the interaction and signal transmission of DC-T cells, and the combination of the two mechanisms can overcome the low response rate problem of the existing DC vaccine, and maximizes the anti-tumor immune response.

An orally bioavailable benzofuran is provided which possesses in vitro and in vivo capabilities able to overcome issues in loading of antigenic peptide on major histocompatibility class I complexes, including on the surface of professional antigen presenting cells. The design of immunotherapies such as dendritic cell vaccines, optimal binding of the antigenic peptides to MHC class I complexes is a major challenge. Current therapeutic peptide loading is expensive, labor-intensive, or requires in vitro manipulation. Models demonstrate that the benzofuran enhances T-cell activation through increased peptide binding to cell surface MHC class I complexes. Molecular docking studies indicate the benzofuran binds the F pocket of MHC class I in a similar manner to high-affinity peptides and TAPBPR, aiding in the targeted loading of exogenous peptides. The therapeutic potential was demonstrated when using PLGA particles of BzFβ were injected intramuscularly, and significantly inhibited the development of E.G7-OVA tumors.

The invention relates to the technical field of biological medicines, in particular to a dendritic cell vaccine for multiple myeloma as well as a preparation method and application of the dendritic cell vaccine, and the dendritic cell vaccine is obtained by co-culturing dendritic cell vaccines MOLP-8, RPMI-8226, NCI-H929, U266B1 and MM1. S whole cell line lysates and dendritic cells. According to the present invention, the whole cell line lysates of MOLP-8, RPMI-8226, NCI-H929, U266B1 and MM1. S are adopted as the antigen of the DC vaccine, and the mixed lysates contain rich tumor antigens, can activate the immune system, and can generate the cytotoxic T cells aiming at the multiple myeloma antigens so as to specifically kill the tumor cells. The DC vaccine prepared by the invention not only stimulates T cells to generate more IFN-gamma, but also induces to generate stronger tumor killing T cells, and provides a new thought for research and development of multiple myeloma DC vaccines.

The present invention discloses the application of atorvastatin calcium in the preparation of an anti-tumor preparation for enhancing dendritic cell vaccines, belonging to the technical field of immune adjuvants. The application of atorvastatin calcium disclosed by the present invention in the preparation of an anti-tumor preparation for enhancing dendritic cell vaccines. Atorvastatin calcium can be used in the preparation of dendritic cell vaccines, significantly up-regulating the expression of pro-inflammatory factors Tnfa, Il6, Il12p40, and Il12p35 and the expression of surface co-stimulatory molecules CD80 and CD86 in dendritic cells, promoting the ability of dendritic cells to mediate the activation of CD4+ T cells and CD8+ T cells and their differentiation into IFNγ-secreting effector cells, and effectively enhancing the anti-tumor effect of dendritic cell vaccines. The present invention provides a method for using atorvastatin calcium in the preparation of dendritic cell vaccines to promote the efficacy of dendritic cell vaccines, providing a new direction for tumor prevention and treatment.

The present invention provides a dual-modal magnetic particle fluorescence probe and its application in the preparation, tracing and monitoring of dendritic cell vaccines, belonging to the field of biotechnology. The dual-modal magnetic particle fluorescence probe includes: magnetic nanoparticles, cell-penetrating peptides, fluorescence resonance energy transfer fluorescence reporter groups and caspase substrates. The dual-modal magnetic particle fluorescence probe of the present invention combines the advantages of nuclear magnetic resonance imaging and fluorescence resonance energy transfer imaging, can provide real-time imaging information in different biological events, has a high signal-to-background ratio and specificity, and can realize the in vivo monitoring of the behavior of dendritic cell vaccines in real time, including processes such as migration, localization and apoptosis, which helps to improve the efficiency and accuracy of vaccine research and application.

The invention belongs to the technical field of biological medicine, and relates to a dendritic cell vaccine as well as a preparation method and application thereof, in particular to a dendritic cell vaccine based on enhancement of dendritic cell maturation and vaccine efficiency and application of the dendritic cell vaccine in tumor treatment. The dendritic cell disclosed by the invention is a dendritic cell with deletion of a metabotropic glutamate receptor 4 or a dendritic cell treated by forskolin, and the dendritic cell can promote the expression of co-stimulatory molecules on the surface of the dendritic cell; the proliferation of T cells is promoted; inducing the effector T cells to secrete interferon gamma and granzyme B; the killing capability of T cells on tumor cells is enhanced. The dendritic cell vaccine disclosed by the invention comprises dendritic cells loaded with antigens, wherein the antigens are liver cancer cell lysates. The dendritic cell vaccine disclosed by the invention has an anti-tumor effect and can be used for preparing anti-tumor medicines.

The present invention belongs to the field of biomedicine, and specifically relates to liposomes modified by hydrophobic modified polypeptides, mRNA delivery systems and dendritic cell vaccines. The technical problem to be solved by the present invention is to improve the immune effect of mRNA vaccines and DCs vaccines sensitized by mRNA. The technical solution to solve the technical problem is to provide a liposome modified by a hydrophobic modified cationic polypeptide. The modified liposomes of the polypeptides of the present invention can efficiently deliver nucleic acids into cells; in particular, they can efficiently deliver mRNA encoding antigens into DCs, significantly improve the efficiency of cationic liposomes in delivering mRNA to DCs, enhance the immune effect of mRNA vaccines and DC vaccines sensitized by mRNA, and have good clinical application prospects.

The invention belongs to the field of biological pharmacy, and particularly relates to application of a Cererin polypeptide combined dendritic cell vaccine in preparation of a medicine for treating breast cancer. It is found that F1 / F3 significantly inhibits proliferation of 4T-1 cells in vitro, induces cell death, significantly inhibits growth of primary tumors in vivo, reduces lung metastasis and prolongs the overall lifetime, and inoculation of a DC vaccine loaded with tumor-associated antigens can reduce tumor growth and enhance T cell activation in drainage and non-drainage lymph nodes. Compared with a vaccine (DCV1) loaded with a holoantigen, the DC vaccine (DCV2) combined with a programmed death antigen induced by F1 / F3 shows higher anti-tumor activity, although the secretion of TNF-alpha and IL-12 is lower. Therefore, the F1 / F3 polypeptide and the DCV2 are combined to prepare the medicine for treating the breast cancer, the tumor treatment effect is effectively improved, and the importance of a combined immunotherapy strategy is highlighted.

The invention belongs to the field of biological medicine products, and relates to an immunological enhancement adjuvant for tumor therapeutic vaccines, which is formed by dissolving thymoquinone serving as an adjuvant active ingredient in a benign thymoquinone solvent in cooperation with necessary pharmaceutic adjuvants. The immunopotentiation adjuvant is suitable for being used as a polypeptide vaccine, a protein vaccine, a nucleic acid vaccine, a tumor cell vaccine, a dendritic cell vaccine and other tumor therapeutic vaccines, promotes IFN-gamma secretion by up-regulating immune-related gene expression in CD8 + T cells, enhances the killing function of the CD8 + T cells, inhibits tumor growth, and improves the tumor therapeutic effect. The immune effect of the tumor therapeutic vaccine is obviously enhanced.

The invention discloses a dendritic cell vaccine preparation and a preparation method thereof, and the method comprises the following steps: collecting fresh breast cancer tissues, and carrying out serum-free culture on the breast cancer tissues to obtain GREM1 positive triple-negative breast globular cells; performing heat shock and repeated freezing and thawing on the GREM1 positive triple-negative mammary gland globular cells to obtain cell lysate; preparing an immature dendritic cell; controlling the cell lysate to load the immature dendritic cells to obtain a load product; and carrying out induced maturation treatment on the loaded product to obtain the vaccine preparation. The dendritic cell vaccine preparation provided by the invention can trigger immune response in vivo and in vitro to kill triple-negative breast cancer cells causing relapse and metastasis, thereby providing possibility for overcoming the tolerance of triple-negative breast cancer and radically treating the relapse and metastasis of triple-negative breast cancer.

Engineered dendritic cell vaccines, and methods of forming and applying same, that may be used as effective immunotherapies for cancers.

The present invention discloses an adjuvant for enhancing the efficacy of dendritic cell vaccines and its application, belonging to the field of biotechnology. The present invention discloses an adjuvant AOAA for enhancing the efficacy of dendritic cell vaccines, which can significantly enhance the immunogenicity of DCs, upregulate the expression of proinflammatory factors IL-6, IL-12, IL-23, TNFα and co-stimulatory molecules CD80 and CD86 in DCs, and promote DC-mediated CD4 + T cells and CD8 + The ability of T cells to differentiate into IFNγ-secreting effector T cells; moreover, AOAA can be used in the preparation of DC vaccines to enhance the anti-tumor effect of DC vaccines.

The invention relates to the technical field of biological medicines, in particular to a method for screening a high-activity dendritic cell vaccine by utilizing CD39 and TIM3, which comprises the step of sorting and / or identifying mature dendritic cells by utilizing biomarkers CD39 and TIM3. According to the invention, CD39 and TIM3 are taken as biomarkers for sorting the mo-DC, the high-activity mo-DC vaccine can be screened out, and experimental results show that the high expression of the biomarkers such as CD11C, HLA-DR and CD197 in the mo-DC vaccine obtained by the method is realized; meanwhile, the experimental result also shows that the T cell proliferation proportion of the CD39 + TIM3 + DC stimulation group is obviously higher than that of the DC stimulation group, which indicates that the DC sorted by the CD39 and TIM3 has strong immune response induction capability and is obviously higher than that of the un-screened moDC-DC group.

The present invention relates to a dendritic cell vaccine for use in the treatment of cancer, wherein the dendritic cell vaccine is administered to a patient in parallel to chemotherapy with at least one chemotherapeutic agent.

The present application relates to the technical field of biomedicine, and relates to the preparation of a dendritic cell vaccine for pancreatic cancer and the use thereof in the preparation of a drug for treating pancreatic cancer. The preparation method comprises the preparation of Panc-1 and AsPC-1 lysates, the preparation of immature dendritic cells, and the preparation of a DC vaccine loaded with the Panc-1 and AsPC-1 lysates.

Methods and materials for treating cancer (e.g., ovarian cancer) using a combination of a Th 17 DC vaccine and an immune checkpoint inhibitor are provided herein.

The invention discloses an engineered potent dendritic cell vaccine as well as a preparation method and application thereof, tumor antigen and cationic liposome are fused by utilizing a nanoscale antigen delivery mode, stability of a lysosomal membrane is destroyed by virtue of interaction of cationic lipid charges, so that part of the antigen escapes into cytoplasm and is crossly presented through an MHC I (major histocompatibility complex I) way, and the dendritic cell vaccine is prepared. Administering DC to activate the ability of cellular immune response to resist tumors; on the other hand, the DC is endowed with T cell guidance through a synthetic immunology method, firstly, the surface of the DC is modified with an azide group N3, a T cell specific antibody is modified with a dibenzocyclooctyne group DBCO, the T cell specific antibody is coupled to the surface of the mature DC through a cycloaddition reaction of the N3 and the DBCO, the chance of contact between the DC and the T cell is increased, the duration time of contact between the DC and the T cell is prolonged, and the T cell specific antibody is coupled to the surface of the mature DC through the cycloaddition reaction of the N3 and the DBCO. The interaction and signal transmission of DC-T cells are promoted; the combination of the two mechanisms can overcome the problem of low reaction rate of the existing DC vaccine, and maximization of anti-tumor immune response is realized.